Subbarao Mylavarapu, MD
Cardiovascular Disease · Newport Beach, CANPI 1659330850
Payments from drug & device makers
Across 553 payments — averaging $529.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cathworks, Inc.$103K
- Edwards Lifesciences$100K
- Microvention, Inc.$62K
- Shockwave Medical, Inc$7K
- Siemens Medical Solutions USA, Inc.$5K
- Cordis US CORP.$4K
- plus $12K from 48 others
Across 2 payments — averaging $2562.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Microvention, Inc.$5K
What the payments were for
- Consulting fees$151,68975%
- Speaking & faculty fees$33,17016%
- Travel & lodging$4,0902%
- Food & beverage$13,4027%
- Education$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRangio System$83,416
- FFRangio$20,000
- HydroCoil Helical$14,500
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$6,759
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$6,415
- Micra$1,119
- Edwards SAPIEN 3 Transcatheter Heart Valve$780
- WEB$625
- Indigo System$235
- Cleerly Ischemia$217
- Cleerly Labs$217
- COREVALVE EVOLUT R$170
- CoreValve Evolut$154
- Legacy$142
- OPTIS$141
- FFRct$136
- XIENCE SIERRA$123
- PRO-Kinetic Energy$113
- PK Papyrus$113
- Astron; Pulsar; AstronPulsar$113
How this compares
$292,781 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 260 | $341,170 |
| XareltoRivaroxaban | 262 | $316,217 |
| EntrestoSacubitril/Valsartan | 88 | $116,008 |
| JardianceEmpagliflozin | 51 | $64,905 |
| FarxigaDapagliflozin Propanediol | 36 | $37,718 |
| Repatha SureclickEvolocumab | 26 | $27,821 |
| Praluent PenAlirocumab | 20 | $19,383 |
| Repatha PushtronexEvolocumab | 15 | $17,836 |
| BrilintaTicagrelor | 20 | $16,791 |
| Repatha SyringeEvolocumab | 16 | $12,681 |
| NexletolBempedoic Acid | 11 | $8,400 |
| Amiodarone Hcl | 85 | $6,192 |
| Atorvastatin Calcium | 438 | $4,431 |
| Potassium Chloride | 79 | $4,263 |
| Prasugrel Hcl | 31 | $4,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $566 | $341,170260 claims |
| Johnson & JohnsonXarelto | $462 | $316,217262 claims |
| NovartisEntresto | $818 | $116,00888 claims |
| Boehringer IngelheimJardiance | $410 | $64,90551 claims |
| AstraZenecaFarxiga, Brilinta | $211 | $54,51056 claims |
| Esperion Therapeutics, Inc.Nexletol | $59 | $8,40011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Newport Beach
- Michael RadinNewport Beach$1.3M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.